Table 3.
Immunized serum protects mice against intranasal challenge with PAO1c
| Challenge dose (CFU) of PAO1 or PBS | Serum dose (fold dilution) | No. of survivors (n = 5) |
|||
|---|---|---|---|---|---|
| 24 h | 48 h | 72 h | 7 days later | ||
| 1.5 × 109 | 5 | 5 | 5 | 5 | 5 |
| 10 | 5 | 5 | 5 | 5 | |
| 20 | 5 | 5 | 5 | 5 | |
| 50 | 4 | 4 | 4 | 4 | |
| Controla | 0 | 0 | 0 | 0 | |
| Controlb | 0 | 0 | 0 | 0 | |
| 1.5 × 1011 | 5 | 5 | 5 | 5 | 5 |
| 10 | 5 | 5 | 5 | 5 | |
| 20 | 5 | 4 | 4 | 4 | |
| 50 | 1 | 1 | 0 | 0 | |
| Controla | 0 | 0 | 0 | 0 | |
| Controlb | 0 | 0 | 0 | 0 | |
| PBS | Not added | 5 | 5 | 5 | 5 |
a
Unimmunized serum.
b
Serum from mice inoculated intranasally with a single dose of OMVs.
c
Protection was significant for serum-injected mice compared with the uninjected group (P < 0.001, determined by the chi-square test with Yates' correction).